- Home
- WCT vs MRKR Comparison
WCT vs MRKR Comparison
Compare WCT & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- MRKR
- Stock Information
- Founded
- WCT 2012
- MRKR N/A
- Country
- WCT Hong Kong
- MRKR United States
- Employees
- WCT N/A
- MRKR N/A
- Industry
- WCT
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- WCT
- MRKR Health Care
- Exchange
- WCT NYSE
- MRKR Nasdaq
- Market Cap
- WCT 13.9M
- MRKR 13.4M
- IPO Year
- WCT 2024
- MRKR N/A
- Fundamental
- Price
- WCT $0.27
- MRKR $1.77
- Analyst Decision
- WCT
- MRKR Strong Buy
- Analyst Count
- WCT 0
- MRKR 3
- Target Price
- WCT N/A
- MRKR $13.17
- AVG Volume (30 Days)
- WCT 1.1M
- MRKR 185.7K
- Earning Date
- WCT 05-16-2025
- MRKR 05-15-2025
- Dividend Yield
- WCT N/A
- MRKR N/A
- EPS Growth
- WCT N/A
- MRKR N/A
- EPS
- WCT N/A
- MRKR N/A
- Revenue
- WCT $2,309,218.00
- MRKR $5,696,123.00
- Revenue This Year
- WCT N/A
- MRKR N/A
- Revenue Next Year
- WCT N/A
- MRKR $11.28
- P/E Ratio
- WCT N/A
- MRKR N/A
- Revenue Growth
- WCT N/A
- MRKR 71.53
- 52 Week Low
- WCT $0.12
- MRKR $0.95
- 52 Week High
- WCT $9.36
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- MRKR 72.77
- Support Level
- WCT N/A
- MRKR $1.12
- Resistance Level
- WCT N/A
- MRKR $1.82
- Average True Range (ATR)
- WCT 0.00
- MRKR 0.17
- MACD
- WCT 0.00
- MRKR 0.06
- Stochastic Oscillator
- WCT 0.00
- MRKR 93.33
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.